Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA (NCT05740683) | Clinical Trial Compass
RecruitingNot Applicable
Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA
Denmark100 participantsStarted 2023-02-01
Plain-language summary
Test of early warning signs and RT-QuIC in patients with idiopathic olfactory dysfunction
Who can participate
Age range55 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria with patients iOD:
* Age 55 -75 years of age
* Slowly progressing and non-fluctuating iOD
* Able to give informed consent and to cooperate as evaluated by the PI
Exclusion criteria with patients iOD:
* Diagnosed with a neurodegenerative disease or major neurological/psychiatric condition.
* Anosmia/hyposmia caused by sino-nasal disease (including chronic rhinitis and allergy), after trauma, infection, congenial, olfactory dysfunction due to surgery, or toxins/drugs affecting the olfactory function.
* Olfactory dysfunction with response to systemic or local corticosteroids if tried
* Severe nasal cavity abnormalities or infections.
* Overt signs of dementia or PD
* Current alcohol or drug abuse
* Terminal illness
* Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.
Inclusion criteria controls:
* Age 55 -75 years of age
* Able to give informed consent
* Able to cooperate as evaluated by the PI
Exclusion criteria controls:
* Olfactory dysfunction on clinical test
* Overt signs of dementia or PD
* Severe nasal cavity abnormalities or infections.
* Current alcohol or drug abuse
* Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.
What they're measuring
1
Real-time quaking-induced conversion (RT-QuIC) positive for alpha-synuclein (aSyn)